EA201490209A1 - Лечение избыточного менструального кровотечения, обусловленного фибромой матки - Google Patents

Лечение избыточного менструального кровотечения, обусловленного фибромой матки

Info

Publication number
EA201490209A1
EA201490209A1 EA201490209A EA201490209A EA201490209A1 EA 201490209 A1 EA201490209 A1 EA 201490209A1 EA 201490209 A EA201490209 A EA 201490209A EA 201490209 A EA201490209 A EA 201490209A EA 201490209 A1 EA201490209 A1 EA 201490209A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
uterus
fiber
caused
menstrual bleeding
Prior art date
Application number
EA201490209A
Other languages
English (en)
Other versions
EA026721B1 (ru
Inventor
Эрнест Луме
Эльке Бештель
Иэн Остерло
Original Assignee
Преглем Са
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44720552&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201490209(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Преглем Са filed Critical Преглем Са
Publication of EA201490209A1 publication Critical patent/EA201490209A1/ru
Publication of EA026721B1 publication Critical patent/EA026721B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Absorbent Articles And Supports Therefor (AREA)
  • Thermotherapy And Cooling Therapy Devices (AREA)

Abstract

Настоящее изобретение в общем смысле относится к доброкачественным гинекологическим заболеваниям и, в частности, к способу и композициям для уменьшения обильных менструаций, сопряженных с указанными гинекологическими заболеваниями, после лечения методами окклюзии сосудов или использования тепловых методов лечения.
EA201490209A 2011-07-12 2012-07-12 Применение улипристала или его метаболитов для нормализации менструального кровотечения EA026721B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161506704P 2011-07-12 2011-07-12
EP11173630A EP2545922A1 (en) 2011-07-12 2011-07-12 Treatment of excessive menstrual bleeding associated with uterine fibroids
PCT/IB2012/053577 WO2013008202A1 (en) 2011-07-12 2012-07-12 Treatment of excessive menstrual bleeding associated with uterine fibroids

Publications (2)

Publication Number Publication Date
EA201490209A1 true EA201490209A1 (ru) 2014-06-30
EA026721B1 EA026721B1 (ru) 2017-05-31

Family

ID=44720552

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201490209A EA026721B1 (ru) 2011-07-12 2012-07-12 Применение улипристала или его метаболитов для нормализации менструального кровотечения

Country Status (17)

Country Link
US (1) US9168264B2 (ru)
EP (2) EP2545922A1 (ru)
JP (1) JP2014520840A (ru)
KR (1) KR101932789B1 (ru)
CN (1) CN103648503A (ru)
AU (1) AU2012282061B2 (ru)
BR (1) BR112014000650A2 (ru)
CA (1) CA2836346A1 (ru)
CO (1) CO6870034A2 (ru)
EA (1) EA026721B1 (ru)
GE (1) GEP20166430B (ru)
HU (1) HUE037294T2 (ru)
IL (1) IL229515B (ru)
MX (1) MX2014000474A (ru)
MY (1) MY165571A (ru)
WO (1) WO2013008202A1 (ru)
ZA (1) ZA201400231B (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2545922A1 (en) 2011-07-12 2013-01-16 PregLem S.A. Treatment of excessive menstrual bleeding associated with uterine fibroids
CA2905214A1 (en) * 2013-03-14 2014-09-18 Laboratoire Hra-Pharma Method for scheduling ovulation
US11110103B2 (en) 2015-12-23 2021-09-07 Oric Pharmaceuticals, Inc. Inhibitors of glucocorticoid receptor
CN108699102A (zh) 2015-12-23 2018-10-23 欧瑞克制药公司 糖皮质激素受体抑制剂
CA3009525A1 (en) 2015-12-23 2017-06-29 Oric Pharmaceuticals, Inc. Inhibitors of glucocorticoid receptor
JP2019506443A (ja) * 2016-02-24 2019-03-07 イースタン バージニア メディカル スクール 改良された持効性注射用デポ型ブタン酸レボノルゲストレル懸濁製剤
EP3851444A1 (en) 2016-10-07 2021-07-21 Oric Pharmaceuticals, Inc. Inhibitors of glucocorticoid receptor

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4954490A (en) 1988-06-23 1990-09-04 Research Triangle Institute 11 β-substituted progesterone analogs
SK282570B6 (sk) * 1995-02-02 2002-10-08 Schering Aktiengesellschaft Antagonisty progesterónu na výrobu liekov na ošetrenie dysfunkčného maternicového krvácania
US5929262A (en) 1995-03-30 1999-07-27 The United States Of America As Represented By The Department Of Health And Human Services Method for preparing 17α-acetoxy-11β-(4-N, N-dimethylaminophyl)-19-Norpregna-4,9-diene-3, 20-dione, intermediates useful in the method, and methods for the preparation of such intermediates
US6900193B1 (en) * 1996-05-01 2005-05-31 The United States Of America As Represented By The Department Of Health And Human Services Structural modification of 19-norprogesterone I: 17-α-substituted-11-β-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents
ES2212912B1 (es) 2003-01-22 2005-10-01 Crystal Pharma, S.A. Procedimiento para la obtencion de 17alfa-acetoxi-11beta-(4-n,n-dimetilaminofenil)-19-norpregna-4,9-dien-3,20-diona.
CA2516319C (en) 2003-02-28 2012-09-18 The Government Of The United States Of America, As Represented By The Se Cretary, Department Of Health And Human Services Method for preparing 17.alpha.-acetoxy-11.beta.-(4-n,n-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione, intermediates thereof, and methods for the preparation of such intermediates
MX2007000273A (es) 2004-07-09 2007-05-21 Population Council Inc Composiciones de liberacion sostenida que contiene moduladores del receptor de progesterona.
DE602006007453D1 (de) * 2005-04-28 2009-08-06 Wyeth Corp Zusammensetzungen mit mikronisiertem tanaproget
EA200800974A1 (ru) 2005-09-29 2008-10-30 Репрос Терапьютикс Инк. Композиции с улучшенной биодоступностью, содержащие стероидное производное и полигликолизированный глицерид
WO2007103510A2 (en) 2006-03-08 2007-09-13 Danco Laboratories Llc Methods, dosing regimens & medications using anti-progestational agents for the treatment of disorders
AU2007339820A1 (en) 2006-12-28 2008-07-10 Repros Therapeutics Inc. Methods and formulations for improved bioavailability of antiprogestins
EP2148681B1 (en) 2007-04-20 2016-03-16 PregLem S.A. Selective progesterone modulators in the treatment of uterine bleeding
WO2009061569A1 (en) * 2007-11-05 2009-05-14 Repros Therapeutics Inc. Compositions and methods for treating dysfunctional uterine bleeding
US8299050B2 (en) 2008-01-29 2012-10-30 Laboratoire Hra-Pharma Method for treating uterine fibroids
AU2009271408A1 (en) 2008-06-18 2010-01-21 Lexicon Pharmaceuticals, Inc. Solid forms of (1R,2S,3R)-1-(2-(isoxazol-3-yl) -1H-imidazol-4-yl)butane-1,2,3,4-tetraol and methods of their use
DE202011110355U1 (de) * 2011-03-09 2014-01-15 Arstat, Inc. Behandlung von Uterusmyomen durch intravaginale Verabreichung einer niedrigen Dosis eines selektiven Progesteronrezeptormodulators, eines Antigestagens oder eines Antigestagen-Wirkstoffes
EP2545922A1 (en) 2011-07-12 2013-01-16 PregLem S.A. Treatment of excessive menstrual bleeding associated with uterine fibroids

Also Published As

Publication number Publication date
ZA201400231B (en) 2014-10-29
IL229515B (en) 2018-01-31
CA2836346A1 (en) 2013-01-17
KR101932789B1 (ko) 2018-12-27
AU2012282061A1 (en) 2014-01-23
AU2012282061B2 (en) 2016-11-10
EP2731613B1 (en) 2017-08-30
CO6870034A2 (es) 2014-02-20
IL229515A0 (en) 2014-01-30
WO2013008202A1 (en) 2013-01-17
US9168264B2 (en) 2015-10-27
EP2545922A1 (en) 2013-01-16
JP2014520840A (ja) 2014-08-25
GEP20166430B (en) 2016-02-10
KR20140050614A (ko) 2014-04-29
NZ619478A (en) 2015-12-24
BR112014000650A2 (pt) 2020-10-27
MX2014000474A (es) 2014-02-20
EP2731613A1 (en) 2014-05-21
CN103648503A (zh) 2014-03-19
US20140148419A1 (en) 2014-05-29
HUE037294T2 (hu) 2018-09-28
MY165571A (en) 2018-04-05
EA026721B1 (ru) 2017-05-31

Similar Documents

Publication Publication Date Title
EA201490209A1 (ru) Лечение избыточного менструального кровотечения, обусловленного фибромой матки
CO2017004715A2 (es) Métodos y formulaciones para tratar enfermedades vasculares de los ojos
EP2381957A4 (en) THERAPEUTIC MODULATION OF VAGINAL EPITHELIUM LIMITING LUBRICATION
PH12016500828A1 (en) (aza) pyridopyrazolopyrimidinones and indazolopyrimidinones as inhibitors of fibrinolysis
CR20200220A (es) FORMAS SÓLIDAS DE ÁCIDO {[5-(3-CLOROFENIL)-3-HIDROXIPIRIDIN-2-CARBONIL]AMINO}ACÉTICO, COMPOSICIONES, Y USOS DE LAS MISMAS (Divisional 2016-0222)
EA201490746A3 (ru) Применение прогестерона при профилактике и после острого периода для улучшения исходов, связанных с сотрясением мозга
DOP2010000282A (es) Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasa
ES2421717T3 (es) Fosfatasa alcalina para aumentar la actividad del sistema inmune en un mamífero con riesgo de enfermedades inflamatorias
EA201390948A1 (ru) Лечение боли, обусловленной смещением базального слоя эндометрия
EA201500851A1 (ru) ЭСТРА-1,3,5(10),16-ТЕТРАЕН-3-КАРБОКСАМИДЫ ДЛЯ ИНГИБИРОВАНИЯ 17β-ГИДРОКСИСТЕРОИД-ДЕГИДРОГЕНАЗЫ (AKR1C3)
TR201900863T4 (tr) Beta-klorosiklopentanların hidrofilik ester ön ilaçlarının kullanılmasıyla merkezi korneal kalınlaşmanın azaltılması.
MX2014010940A (es) El uso de antitrombina en el tratamiento de preeclampsia.
AR091739A1 (es) Composiciones y metodos para reducir el riesgo cardiometabolico
MY185108A (en) Method for treatment of labor arrest
GB2525835A (en) Composition comprising a diindolymethane and a retinoid to treat a skin condition
WO2013059233A3 (en) Thermoresponsive compositions for dermatological use and methods thereof
WO2011091154A3 (en) Use of human erythrocytes for prevention and treatment of cancer dissemination and growth
MX2011011062A (es) Derivados de tioxanteno para el tratamiento de enfermedades infecciosas.
EA201071350A1 (ru) Композиции и способы для лечения воспаления роговицы
EA201491836A1 (ru) Способы лечения рака с использованием ингибитора pi3k и ингибитора mek
CL2008003070A1 (es) Metodo de tratamiento de hemorragia uterina disfuncional que comprende administrar a un paciente una cantidad eficaz de una composicion que comprende un compuesto derivado de antagonistas de progesterona.
RU2012129895A (ru) Средство для профилактики синдрома послеродового стресса у коров голштинской породы в период адаптации к муссонному климату
HK1206271A1 (en) Application of 18-methyl-15,16-methylene-19-nor-20-spirox-4-en-3- one in the treatment of menorrhagia, as well as intrauterine systems containing 18-methyl-15,16-methylene-19-nor-20-spirox-4-en-3-one for treating uterine bleeding disorders 18--1516--19--20--4--3- 18--1516--19-- 20--4--3-
UA36759U (ru) Способ лазерно-микрохирургического удаления внутримозговых опухолей полушарий большого мозга с медианным распространением
UA64531U (ru) Способ мобилизации сегмента магистральной вены в зоне артериовенозной мальформации

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM RU